NASDAQ:QDEL - QuidelOrtho Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $105.00
  • Forecasted Upside: 8.12 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 1 Strong Buy Ratings
$97.11
▼ -0.07 (-0.07%)

This chart shows the closing price for QDEL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New QuidelOrtho Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for QDEL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for QDEL

Analyst Price Target is $105.00
▲ +8.12% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for QuidelOrtho in the last 3 months. The average price target is $105.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 8.12% upside from the last price of $97.11.

This chart shows the closing price for QDEL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in QuidelOrtho. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/11/2021
  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/11/2021
  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/10/2021
  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/8/2021
  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/6/2022
  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/6/2022
  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/5/2022
  • 1 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/5/2022

Latest Recommendations

  • 1 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/17/2022JPMorgan Chase & Co.Initiated CoverageUnderweight ➝ NeutralHigh
2/22/2022Raymond JamesUpgradeOutperform ➝ Strong-Buy$155.00 ➝ $130.00High
10/8/2021JPMorgan Chase & Co.Boost Price TargetOverweight$70.00 ➝ $80.00Medium
8/6/2021Raymond JamesBoost Price TargetOutperform$141.00 ➝ $155.00Low
6/28/2021Raymond JamesLower Price TargetOutperform$160.00 ➝ $141.00High
6/17/2021Craig HallumLower Price TargetBuy$296.00 ➝ $219.00Low
6/4/2021JPMorgan Chase & Co.Lower Price TargetUnderweight$90.00 ➝ $80.00High
5/7/2021Raymond JamesLower Price TargetOutperform$180.00 ➝ $160.00High
5/7/2021JPMorgan Chase & Co.Lower Price TargetUnderweight$95.00 ➝ $90.00High
4/23/2021JPMorgan Chase & Co.Lower Price Target$120.00 ➝ $95.00High
4/23/2021Piper SandlerLower Price Target$265.00 ➝ $140.00High
3/17/2021Raymond JamesLower Price TargetOutperform$245.00 ➝ $180.00N/A
3/11/2021Craig HallumLower Price TargetBuy$371.00 ➝ $341.00Low
3/11/2021Raymond JamesLower Price TargetOutperform$245.00 ➝ $180.00Low
2/25/2021Raymond JamesLower Price TargetOutperform$250.00 ➝ $245.00Medium
2/19/2021JPMorgan Chase & Co.Lower Price TargetUnderweight$175.00 ➝ $170.00High
1/22/2021Raymond JamesUpgradeMarket Perform ➝ Outperform$250.00High
10/30/2020JPMorgan Chase & Co.Boost Price TargetUnderweight$185.00 ➝ $190.00Medium
7/31/2020Craig HallumBoost Price TargetPositive ➝ Buy$306.00 ➝ $363.00Medium
7/31/2020Piper SandlerBoost Price TargetOverweight$250.00 ➝ $360.00High
7/8/2020Piper SandlerBoost Price TargetOverweight$168.00 ➝ $250.00Medium
7/7/2020Craig HallumBoost Price TargetBuy$170.00 ➝ $306.00Medium
5/12/2020JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$120.00 ➝ $158.00High
5/7/2020Craig HallumBoost Price TargetMarket Perform ➝ Buy$125.00 ➝ $170.00Medium
3/26/2020BarclaysReiterated RatingOverweight ➝ Equal Weight$90.00High
3/19/2020Raymond JamesDowngradeStrong-Buy ➝ Market PerformHigh
2/13/2020Raymond JamesBoost Price TargetStrong-Buy$70.00 ➝ $92.00Medium
8/29/2019Craig HallumUpgradeHold ➝ Buy$63.00 ➝ $75.00High
4/15/2019Raymond JamesBoost Price TargetStrong-Buy ➝ Strong-Buy$72.00 ➝ $74.00Medium
3/18/2019BarclaysBoost Price TargetOverweight ➝ Overweight$74.00 ➝ $77.00High
2/15/2019BarclaysReiterated RatingBuy$74.00Low
2/14/2019Craig HallumBoost Price TargetHold$51.00 ➝ $63.00High
12/11/2018Raymond JamesLower Price TargetStrong-Buy ➝ Strong-Buy$80.00 ➝ $70.00Medium
12/10/2018Craig HallumDowngradeBuy ➝ Hold$80.00 ➝ $51.00High
12/10/2018BarclaysLower Price TargetOverweight ➝ Overweight$85.00 ➝ $77.00High
10/23/2018Raymond JamesReiterated RatingStrong-Buy ➝ Strong-Buy$80.00Medium
8/8/2018Craig HallumBoost Price TargetBuy$64.00 ➝ $80.00High
8/8/2018Piper Jaffray CompaniesReiterated RatingIn-Line ➝ Overweight$74.00High
8/6/2018BarclaysBoost Price TargetOverweight ➝ Overweight$65.00 ➝ $78.00Medium
5/10/2018BarclaysReiterated RatingBuy$65.00High
4/13/2018William BlairReiterated RatingBuyLow
4/4/2018Piper Jaffray CompaniesReiterated RatingBuy$63.00Low
4/2/2018BarclaysBoost Price TargetOverweight ➝ Overweight$60.00 ➝ $63.00Low
3/26/2018Craig HallumInitiated CoverageBuy$62.00Low
3/8/2018Raymond JamesUpgradeOutperform ➝ Strong-Buy$55.00 ➝ $47.00Medium
3/8/2018UBS GroupUpgradeOutperform ➝ Strong-BuyHigh
1/24/2018Piper Jaffray CompaniesReiterated RatingBuy$60.00Low
1/22/2018BarclaysBoost Price TargetOverweight ➝ Overweight$50.00 ➝ $60.00High
1/4/2018CL KingUpgradeNeutral ➝ Buy$52.00High
12/14/2017Piper Jaffray CompaniesReiterated RatingBuy$50.00Low
11/3/2017Piper Jaffray CompaniesReiterated RatingBuy$50.00N/A
11/2/2017BarclaysBoost Price TargetOverweight$45.00 ➝ $49.00N/A
9/19/2017BarclaysReiterated RatingBuy$39.00 ➝ $45.00High
9/19/2017Raymond JamesReiterated RatingBuy$41.00 ➝ $47.00High
9/19/2017Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$35.00 ➝ $50.00High
7/27/2017Raymond JamesBoost Price TargetOutperform$36.00 ➝ $41.00High
7/27/2017BarclaysBoost Price TargetOverweight$36.00 ➝ $39.00High
7/18/2017William BlairUpgradeMarket Perform ➝ OutperformHigh
(Data available from 7/5/2017 forward)

News Sentiment Rating

0.34 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/7/2021
  • 16 very positive mentions
  • 39 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
1/6/2022
  • 2 very positive mentions
  • 18 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
2/5/2022
  • 5 very positive mentions
  • 37 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/7/2022
  • 3 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/6/2022
  • 5 very positive mentions
  • 19 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/6/2022
  • 5 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/5/2022
  • 3 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/5/2022

Current Sentiment

  • 3 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
QuidelOrtho logo
QuidelOrtho Corporation provides various in vitro diagnostics products worldwide. The company's product portfolio covers a range of point-of-care tests for infectious diseases, critical cardiac health and autoimmune biomarkers, and clinical and at-home products to detect COVID-19. It provides visually-read lateral flow products in infectious disease and reproductive health; direct fluorescent antibodies in infectious disease and virology; micro-titer production with a focus on bone and complement pathway markets; fluorescent immunoassay products; molecular diagnostic products comprising Savanna, an integrated molecular diagnostic system; immunodiagnostics, clinical chemistry, and integrated testing systems to serve diagnostic labs of all sizes; immunodiagnostic donor screening systems and services that drive blood safety; pre-transfusion testing that automates blood bank workload with software to standardize operations, simplify tasks, and improve productivity; and Ortho Care services and informatics products. The company was founded in 1979 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $97.11
Low: $95.17
High: $97.71

50 Day Range

MA: $98.37
Low: $89.06
High: $104.82

52 Week Range

Now: $97.11
Low: $88.05
High: $180.06

Volume

20,497 shs

Average Volume

682,928 shs

Market Capitalization

$4.06 billion

P/E Ratio

4.10

Dividend Yield

N/A

Beta

0.04

Frequently Asked Questions

What sell-side analysts currently cover shares of QuidelOrtho?

The following sell-side analysts have issued reports on QuidelOrtho in the last twelve months: JPMorgan Chase & Co., Raymond James, StockNews.com, and TheStreet.
View the latest analyst ratings for QDEL.

What is the current price target for QuidelOrtho?

0 Wall Street analysts have set twelve-month price targets for QuidelOrtho in the last year. Their average twelve-month price target is $105.00, suggesting a possible upside of 8.1%.
View the latest price targets for QDEL.

What is the current consensus analyst rating for QuidelOrtho?

QuidelOrtho currently has 1 hold rating and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe QDEL will outperform the market and that investors should add to their positions of QuidelOrtho.
View the latest ratings for QDEL.

How do I contact QuidelOrtho's investor relations team?

QuidelOrtho's physical mailing address is 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA, 92121. The company's listed phone number is (858) 552-1100 and its investor relations email address is [email protected] The official website for QuidelOrtho is www.quidel.com. Learn More about contacing QuidelOrtho investor relations.